| Document |
Document Title |
|
WO/2024/020067A1 |
A maturation medium and a method for maturing an early embryonic human heart organoid into a mature human heart organoid are provided herein. The maturation medium includes a cell growth medium containing a medium supplement including on...
|
|
WO/2024/017326A1 |
Provided in the present disclosure are an antibody against G-protein-coupled receptor C5 family subtype D (GPRC5D), and the use thereof. Specifically, disclosed in the present application are a nanobody or an antigen-binding fragment the...
|
|
WO/2024/018018A1 |
The present invention relates to the use of a vitisin compound for amplifying and/or differentiating hematopoietic cells. The invention also relates to a method for the in vitro production of erythroid progenitors, comprising contacting ...
|
|
WO/2024/020413A1 |
Disclosed herein are methods of producing a population of modified CD4+T cells expressing nuclear IL-37. Also disclosed are methods of using the modified CD4+T cells expressing nuclear IL-37 for the treatment of immune or inflammatory di...
|
|
WO/2024/020365A1 |
The technology described herein is directed to improved methods of T cell differentiation. Also described herein are immune cells differentiated using such methods and compositions comprising such immune cells. In some embodiments, the i...
|
|
WO/2024/017538A1 |
In vitro process for producing organoids from mammalian cells, the process comprising or the steps of cultivating pluripotent stem cells (PSC) in cell culture medium in a stirred tank bioreactor under conditions suitable for producing PS...
|
|
WO/2024/015822A1 |
Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
|
|
WO/2024/015724A1 |
A ribonucleic acid comprising two non-natural pre-miRNA sequences, wherein each pre-miRNA sequence comprises a guide miRNA that inhibits the expression of an immune checkpoint protein. The pre-miRNA sequences may target a different gene ...
|
|
WO/2024/015643A1 |
The present disclosure relates to an in vitro method of inducing reproductive differentiation in a vegetative somatic plant cell. This method involves applying mechanical stress and directional force to a vegetative somatic plant cell en...
|
|
WO/2024/012578A1 |
A non-human animal expressing a human or chimeric TLR7 and/or TLR8 protein, and a usage method therefor.
|
|
WO/2024/011774A1 |
Disclosed in the present invention are a monoclonal antibody against HLA-G2 and HLA-G6 molecules and the use thereof. The antibody (YWHG-26) is produced from a hybridoma with the deposit number of CCTCC NO:C202240, wherein the common seq...
|
|
WO/2024/014721A1 |
The present invention relates to an anticancer composition comprising stem cell-derived exosomes and a preparation method therefor, the composition, according to the present invention, having an excellent anticancer effect and thus being...
|
|
WO/2023/169528A9 |
A red blood cell targeting PD-1, an engineered red blood cell carrying an anti-PD-1 antibody, a preparation method therefor, and a method for treating cancers, in particular anti-PD-1 antibody insensitive or tolerant cancers, and use the...
|
|
WO/2024/011320A1 |
The present disclosure provides methods of generating atrioventricular node like pacemaker cells in tissue culture and methods of using these cells.
|
|
WO/2024/016001A2 |
The present disclosure relates to the generation of antibody-producing, three dimensional, immune organoids. The disclosure also provides methods useful for producing such immune organoids.
|
|
WO/2024/014560A1 |
Provided are: an expression vector into which a gene encoding parasporin (hereinafter, referred to as "PS") is inserted and with which a pharmaceutical composition applicable to the treatment of cancer can be achieved; a cell into which ...
|
|
WO/2024/015988A1 |
In general, the present disclosure relates to the discovery that T cells expressing IL-9R are more efficacious against cancer when administered in combination with the IL-9 cytokine. The combination can allow for the T cells to effect an...
|
|
WO/2024/015734A1 |
Provided are recombinant cytokine receptors that comprise an IL-2 intracellular domain and an extracellular domain that binds to a cytokine other than IL-2. Also provided herein are Treg cell comprising recombinant cytokine receptors and...
|
|
WO/2024/012420A1 |
Disclosed are a universal cell for expressing FASLG, and a preparation method therefor and the use thereof. By means of inactivating major histocompatibility complex (MHC) class I and II genes in cells and overexpressing the FASLG protei...
|
|
WO/2024/015568A2 |
This disclosure relates to bioink compositions for the fabrication of hydrogels or cell-laden hydrogel constructs comprising methacrylated polyethylene glycol and methacrylated gelatin. In certain embodiments, this disclosure relates to ...
|
|
WO/2024/014502A1 |
The purpose of the present invention is to provide a novel antibody production method. Provided is a method for producing an antibody capable of binding to an extracellular vesicle, the method comprising: (1) a step for bringing an antib...
|
|
WO/2024/016003A2 |
An engineered AAV capsid is provided, in which at least one protein on the capsid is modified to include a n-mer motif, which promotes transduction of the capsid into the central nervous system (CNS) through interaction with the Transfer...
|
|
WO/2024/015329A1 |
The present disclosure provides compositions and methods for preparing autologous satellite cells that have restored a dysfunctional gene involved in muscular dystrophy of a patient. Such implanted satellite cells can promote repair and ...
|
|
WO/2024/015846A1 |
An edible scaffold for cultured meat production. The scaffold comprises a polysaccharide and a plant-based protein formed of fibers, microcarriers, or other structural elements. The structural elements can comprise a diameter between abo...
|
|
WO/2024/014317A1 |
[Problem] To provide a cell culture device that, when culturing adherent cells with a bag-shaped culture container, makes it possible to efficiently separate the adherent cells from the culturing surface and obtain a single cell. [Soluti...
|
|
WO/2024/013301A1 |
An assay plate system (1100) for assaying a cell culture model such as an organoid is described. The assay plate system comprises an assay plate (200) comprising an upper surface (201) and comprising a grid array of wells comprising at l...
|
|
WO/2024/015871A2 |
This disclosure describes methods and apparatuses for creating or using a fibrous cell substrate that is formed in a mold using temperature and wettability gradients and that upon which cells can be grown. The disclosed method can includ...
|
|
WO/2024/015480A1 |
Provided herein are methods and systems to selectively deplete a biological sample of host compartments and/or host nucleic acid while enriching the sample microbial compartments and/or related microbial nucleic acid. In addition, provid...
|
|
WO/2024/014956A1 |
The invention is in the field of culturing a homocellular cell culture of progenitor cells form a heterocellular tissue sample. The invention relates to a method for specifically generating muscle progenitor cells or adipogenic progenito...
|
|
WO/2024/012495A1 |
A chimeric antigen receptor (CAR) specifically binding to a CD5 protein, comprising a CD5 binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. Further provided is an engineered immune ef...
|
|
WO/2024/015813A1 |
Provided are methods and compositions for cryopreserving subpopulations of lymphocytes. In one aspect, provided herein is a method of generating a sub-population of lymphocytes from a biological sample, the method comprising cryopreservi...
|
|
WO/2024/014137A1 |
The present disclosure includes, inter alia, a composition for inducing immunotolerance, the composition containing laeverin.
|
|
WO/2024/011335A1 |
The present invention relates to the field of biomedicine, and in particular relates to a modified immune cell. Specifically, disclosed in the present invention are a modified immune cell that overexpresses transcription factors of the n...
|
|
WO/2024/014976A1 |
The group of inventions relates to the fields of biotechnology, plant cultivation, pharmacognosy and biochemistry, and more particularly to a device and method for delivering target components to the intercellular space of plant tissues ...
|
|
WO/2024/014377A1 |
Provided is a composition that has exceptional salt resistance and is useful as a 3D printing support or a 3D cell culture support. A composition for a 3D printing support or a 3D cell culture support, the composition containing compon...
|
|
WO/2024/011319A1 |
The present invention is directed to nucleic acids, vectors, compositions, kits, and cell lines comprising US11 5' leader sequence (SEQ ID NO: 1 or SEQ ID NO: 4), UL27 5' leader sequence (SEQ ID NO: 7 or SEQ ID NO: 10), or UL19 5' leader...
|
|
WO/2024/011360A1 |
The present disclosure relates to a survival stress-based screening system and a high-throughput screening device. Particularly, the present disclosure relates to a fusion protein composition, fusion proteins, a recombinant nucleic acid ...
|
|
WO/2024/014517A1 |
A cell culture method including a culture step for culturing cells, said cells being in contact with a collagen gel containing type III collagen; a production method of a therapeutic composition including a culture step for culturing cel...
|
|
WO/2024/013677A1 |
The present invention provides a biomaterial for immunomodulation comprising aggregates of phenotypically stabilized cells. Said biomaterial is meant to be preferentially administered in a limited location and provides immunomodulation f...
|
|
WO/2024/014470A1 |
To develop a new tumor preventative/therapeutic. Provided are: an agent for preventing and/or treating a tumor, the agent containing, inter alia, an IKZF1ΔE5 protein, which is a deletion variant of IKZF1 in which part or all of exon 5...
|
|
WO/2024/013743A1 |
An in vitro culture model for inflammation is provided. The method comprises tissue cells and immune cells, wherein the tissue cells and immune cells are of different species and are in direct contact. Also provided is an in vitro method...
|
|
WO/2024/012300A1 |
A gene editing method and use. The method comprises: using a base editing system for the deamination of a target C base and/or a target A base on a target polynucleotide, so as to introduce a stop codon or a point mutation start codon in...
|
|
WO/2024/012585A1 |
Provided are a novel chimeric antigen receptor and a combination thereof with a PD1 inhibitor. Further provided are expression vectors and host cells expressing the chimeric antigen receptor and the composition of said receptor with the ...
|
|
WO/2024/014501A1 |
To provide an antibody or an antigen-binding fragment thereof that is useful in testing for cancer, especially early cancer. An antibody, or an antigen-binding fragment thereof, that includes a heavy chain CDR1 including an amino acid se...
|
|
WO/2024/014752A1 |
The present invention relates to a method for forming a hair-follicle-like structure through the co-culturing of human hair-follicle-derived immortalized dermal papilla cells and keratinocytes. Specifically, it has been identified that, ...
|
|
WO/2024/011449A1 |
Disclosed is a use of retinal pigment epithelial cells in replacement of corneal endothelial cells, and prevention and treatment of diseases or symptoms such as corneal endothelial function decompensation. The retinal pigment epithelial ...
|
|
WO/2024/013742A1 |
Cells comprising a heterologous nucleic acid sequence that encodes for a trehalase enzyme and optionally a heterologous nucleic acid sequence that encodes for a trehalose transporter protein are provided. Pharmaceutical compositions comp...
|
|
WO/2024/015743A1 |
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen VCY CT...
|
|
WO/2024/014497A1 |
The purpose of the present invention is to provide: a fibrin gel sheet for cell transplantation, in which cells are enclosed uniformly dispersed while at the same time the sheet has a larger size than heretofore available; and a method f...
|
|
WO/2024/012513A1 |
Provided are antibodies and antigen-binding fragments thereof, and in particular to such antibodies and antigen-binding fragments that have affinity and activity of stimulating T cell activation. Uses of such antibodies and antigen-bindi...
|
